
Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Loading news...

Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

APG Asset Management N.V. lifted its holdings in Danaher Corporation (NYSE: DHR) by 3.5% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 408,682 shares of the conglomerate's stock after acquiring an additional 13,967 shares during the quarter. APG Asset Management N.V. owned

Choreo LLC trimmed its position in shares of Danaher Corporation (NYSE: DHR) by 20.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,894 shares of the conglomerate's stock after selling 3,742 shares during the quarter. Choreo LLC's holdings in

DNB Asset Management AS lowered its stake in shares of Danaher Corporation (NYSE: DHR) by 2.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 163,932 shares of the conglomerate's stock after selling 3,560 shares during the period. DNB Asset Management AS's holdings in Danaher

Getinge (OTCMKTS:GNGBY - Get Free Report) and Danaher (NYSE: DHR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends. Volatility and Risk Getinge has a beta of 1.08, meaning

Artisan Partners Limited Partnership trimmed its position in Danaher Corporation (NYSE: DHR) by 6.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,497,958 shares of the conglomerate's stock after selling 175,013 shares during the period. Artisan Partners

Shares of Danaher Corporation (NYSE: DHR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-three analysts that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and twenty have assigned a buy recommendation to the company. The average 1 year

During the fourth quarter, we initiated a new position in the leading energy-focused specialty contracting company, Quanta Services. Within the existing portfolio, our biggest addition during the quarter was to MSCI, a leading provider of indexes and investment decision support tools. We also added to our position in Danaher Corporation.

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday, March 3, 2025 at 1:50 p.m.

Clearstead Advisors LLC grew its position in shares of Danaher Corporation (NYSE: DHR) by 4.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 93,939 shares of the conglomerate's stock after buying an additional 3,589 shares during the period. Clearstead Advisors LLC's

Avalon Trust Co lifted its holdings in Danaher Corporation (NYSE: DHR) by 5.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,807 shares of the conglomerate's stock after purchasing an additional 3,847 shares during the period. Danaher comprises 1.0% of

Beverly Hills Private Wealth LLC bought a new position in shares of Danaher Corporation (NYSE: DHR) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,382 shares of the conglomerate's stock, valued at approximately $671,000. Other large investors have also

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Masimo will receive $180.00 in cash for each share of Masimo that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

Danaher (NYSE: DHR) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share.

Exploring the Latest 13F Filing and Investment Adjustments Daniel Loeb (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, pr

Danaher has announced its plan to acquire Masimo (MASI) for $180 per share in an all-cash transaction. This represents a 38% premium over Masimo's previous clos

Medical technology stock Masimo Corp (NASDAQ:MASI) is soaring today, last seen up 34.3% to trade at $174.78, after reports that the company is nearing an agreement to be acquired by Danaher Corp (NYSE:DHR) in an all-cash deal worth roughly $10 billion.

Danaher Corporation (NYSE:DHR) announced it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) in an all-cash transaction valued at approximately $9.9 billion, as the life sciences and diagnostics company looks to expand its patient monitoring capabilities. Under the terms of the agreement, Danaher will acquire all outstanding Masimo common shares for $180 per share in cash.

Danaher will acquire pulse oximeter maker Masimo for $9.9 billion, the company said on Tuesday, as the contract research firm looks to bulk up its diagnostics portfolio.